The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
{{output}}
GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. Nevertheless, GLP-1RA therapy is associated with a pattern of adverse events affecting... ...
